正常者ならびに各種内分泌代謝疾患患者におけるL-dopaに対するGHRHおよびGHの分泌反応
スポンサーリンク
概要
- 論文の詳細を見る
The responses of plasma growth hormone-releasing hormone (GHRH) and growth hormone (GH) to oral administration of L-dopa were studied in normal subjects and patients with various endocrine and metabolic diseases to clarify the pathophysiological role of the GHRH-GH axis.<BR>In normal subjects, the plasma GHRH concentration was increased from the basal value of 9.8±1.4pg/ml (mean±SE) to 34.8±3.1pg/ml at 30-90 min after oral administration of 500mg L-dopa, followed by a rise of GH release (plasma GH level from <1ng/ml to 21.7±4.7ng/ml) in most cases, indicating that L-dopa stimulates GH secretion via hypo-thalamic GHRH.<BR>On L-dopa administration, no apparent increases in both plasma GHRH and GH concentrations were observed in patients with hypothalamic hypopituitarism, whereas GHRH administration induced almost normal GH response.<BR>In patients with acromegaly, the plasma levels of GHRH remained stationary after the L-dopa administration and did not correlate with plasma GH levels.<BR>In subjects with simple obesity, the responses of plasma GHRH (peak 13.2±1.2pg/ml) and GH (peak 4.3±1.7ng/ml) to L-dopa were significantly lower than those in normal subjects (p<0.01).<BR>In patients with primary hypothyroidism, peak levels of plasma GHRH (12.6±1.3pg/ ml) and GH (2.4±0.6ng/ml) were significantly lower than those in normal subjects (p<0.01).<BR>In patients with non-insulin dependent diabetes mellitus (NIDDM), the responses of GHRH and GH were divided into 2 groups; in the responder the peak values of GHRH and GH were 19.4±8.6pg/m and 12.2±1.4ng/ml and in the low or non responder 14.7±1.5pg/ml and 2.0±0.6ng/ml, respectively. Between both groups, there was a significant difference in the values of fasting blood sugar and HbA<SUB>1</SUB> and mean suffering period.<BR>These findings suggest that GH secretion evoked by the L-dopa administration is induced by GHRH released from the hypothalamus, and impairment of GH secretion associated with simple obesity, primary hypothyroidism, or NIDDM may be in part attributed to insufficiency of GHRH release from the hypothalamus, and indicate that L-dopa test is clinically useful for evaluating the ability of intrinsic GHRH release in such diseased states.
- 一般社団法人 日本内分泌学会の論文
著者
-
斎藤 史郎
徳島大学医学部中央臨床検査部
-
宮崎 修一
徳島大学医学部第一内科
-
山崎 柳一
徳島大学医学部第一内科
-
斎藤 晴比古
徳島大学医学部内科学第一教室
-
斎藤 晴比古
徳島大学医学部第一内科学教室
-
山崎 柳一
徳島大学医学部第一内科学教室
-
三橋 信次
徳島大学医学部第一内科学教室
関連論文
- プライマリ・ケア医による糖尿病合併症の調査
- 老年者高血圧症の予後調査 : 死因および心血管合併症について
- ペプチドホルモン産生異常症
- 4者 (TRH, LHRH, GHRH, CHR) 同時負荷試験による下垂体手術前後での下垂体前葉機能予備能に関する検討
- 不顕性ACTH細胞腫の4例
- Duchenne型筋ジストロフィーの女性保因者における心機能障害
- Bromocriptine (ブロモクリプチン)
- 視床下部症候群を呈し,経過中に急性腎不全を合併したHCG産生鞍上部胚芽腫の1例
- 筋肉内出血をきたし,第IX, X因子欠乏を認めた原発性アミロイドーシスの1例
- Kallmann症候群の1剖検例